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end of 2007 and linked with the National mortality database. Kaplan–Meier method
was used to yield the estimated survival function of both groups. Constant excess 
hazard model was used to project the long-term survival of these patients by utilizing 
linear extrapolation. Life expectancy was estimated while EYLL was calculated by
subtracting the life expectancy of patients from those of their age- and gender-matched
referents. HD patients were then matched with PD patients on age, gender, and dia-
betic status. Life expectancy, EYLL and survival for the two groups were re-compared. 
Cox Model was applied to determine the risks for mortality. RESULTS: A total of 
305 HD and 428 PD patients were included. Before matching, HD patients were older 
than PD patients (62.4 o 13.7 versus 53.1 o 16.7 years, p  0.0001), and more HD 
patients had diabetes mellitus (DM) (HD versus PD, 29.2% versus 20.6%, p 
0.0072). Life expectancy and EYLL of HD patients were 8.8 and 11.5 years, compared
with those of PD patients (19.9 and 7.4 years). After matching, 236 pairs of HD and
PD patients were selected. Life expectancy (p  0.790) and EYLL (p  0.793) of both 
groups were similar on re-analysis. Age (adjusted hazard ratio, AHR 1.07, 95% CI 
1.05–1.09) and DM (AHR 3.81, 95% CI 2.28–6.36) were independent predictors of 
mortality. For diabetic patients, survival was better if the patients were treated with 
HD (AHR 0.24, 95% CI 0.11–0.53). CONCLUSIONS: After matching, life expec-
tancy and EYLL between HD and PD patients were similar, but survival was better
for diabetic patients if they were treated with HD.
PUK6
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OBJECTIVES: To determine the proportion of OAB patients potentially at risk for
adverse events by assessing CV co-morbidity as measured during the six months prior 
to OAB diagnosis/treatment by biologic measures, CV diagnoses, and CV concomitant 
drug use among treated and untreated OAB patients. METHODS: The GE Centricity 
EMR database was utilized to identify patients with a diagnosis of OAB using ICD-9 
codes or a prescription between January 1, 1996 to March 30, 2007 for an OAB
antimuscarinic agent. The treated OAB patients with 13 months of continuous eligibil-
ity pre- and post-index date formed the OAB cohort. Based on the presence of q1 
pharmacy claim for an OAB antimuscarinic agent, the OAB cohort was stratiﬁ ed as
treated or untreated. A random sample of age and gender matched patients formed a 
comprehensive non-OAB control cohort; they had no diagnosis of OAB, urinary 
bladder dysfunction, or pharmacy claim for an OAB antimuscarinic agent. RESULTS:
OAB patients (N: 41,440; 83.6% women; median age 65 years), when compared to
non-OAB patients (N: 77,272; 83.2% women; median age 64 years), were more likely 
to have CV comorbidities (57.6% vs. 44.6%; p  0.001), a high heart rate (q80 beats 
/ minute) (31.4% vs. 19.9%; p  0.001), higher Framingham risk (9.9% vs. 9.6%; p 
 0.005) as well as use of CV medications (57.1% vs. 38.8%; p  0.001). In treated 
vs. untreated OAB patients, CV comorbidities (58.8% vs. 53.7%; p  0.001), propor-
tion with a high heart rate (32.3% vs. 27.6%; p  0.001) and Framingham risk (10.2% 
vs. 8.6%; p  0.001) and use of CV medications (60.7% vs. 42.4%; p  0.001) also
differed. CONCLUSIONS: CV comorbidities were more prevalent in OAB patients 
than in patients without OAB. Among the OAB patients, CV co-morbidity and prior 
exposure to CV medications was more prevalent in those who received antimuscarinic
treatment than in patient who did not receive treatment.
URINARY/KIDNEY DISORDERS – Cost Studies
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OBJECTIVES: This study evaluates the difference in total hospital charges and length
of stay (LOS) between peritoneal dialysis (PD) and hemodialysis (HD) patients.
METHODS: Hospital inpatient data was analyzed from the Healthcare Cost and 
Utilization Project’s 2006 National Inpatient Sample. Patients were identiﬁ ed as HD 
or PD by a procedure code of 39.95 or 54.98, respectively, and a diagnosis code for 
end-stage renal disease (585.6). Exclusion criteria include having a procedure code for 
both PD and HD, a diagnosis code for acute renal failure (584.x), or under age 18. 
Differences in LOS and total charges were analyzed using univariate and multivariate
analysis adjusted for age, gender, and comorbidities. Subgroup analyses were done by 
payer type. RESULTS: 530,409 HD and 22,031 PD discharges met inclusion and 
exclusion criteria. PD patients were younger, more female, and had less comorbidity. 
The mean total charge for a PD discharge was $35,846 compared to $41,336 for HD 
(p  0.0001). The mean LOS was 6.57 days for PD and 7.25 days for HD (p  0.0001).
After adjusting for covariates, HD total charges were 13.9% higher than PD (p 
0.0001) and LOS was 6.7% longer (p  0.0086). For Medicare patients, total charges 
were 10.0% higher in HD patients (p  0.0001) and LOS was not different between 
HD and PD. For patients with private insurance, mean total charges were 21.7%
higher in HD patients (p  0.0001) and LOS was 9.2% greater (p  0.01). The charge
difference, HD minus PD, between private and Medicare patients was signiﬁ cantly
higher in the former. CONCLUSIONS: Adjusted mean total charges and LOS were 
signiﬁ cantly higher in patients receiving HD compared to PD. LOS was signiﬁ cantly 
longer in privately insured HD patients but not in Medicare HD patients. The charge 
difference between HD and PD was signiﬁ cantly higher in privately insured compared 
to Medicare patients.
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OBJECTIVES: The objective of this study was to determine the cost effectiveness of 
paricalcitol versus standard treatment in patients with chronic kidney disease (CKD)
in the health care setting in Italy, Portugal and Turkey in 2008. METHODS: A Markov 
process model was developed employing data sources from the published literature,
paricalcitol clinical trials, ofﬁ cial country price/tariff lists and national population 
statistics. The comparator was the standard treatment for each country; Italy, Portugal,
and Turkey. The primary perspective of the study was that of the society. The primary 
efﬁ cacy outcome in the Paricalcitol (reduction SHPT, reduction proteinuria, complica-
tions and mortality) were extrapolated to effectiveness outcomes: number of life years 
gained (LYG) and number of quality-adjusted life-years (QALYs). Clinical and eco-
nomic outcomes were discounted at 3.0%. RESULTS: The base case analysis is based
on a 10-years time horizon and a comparison of paricalcitol in stage CKD 3, CKD 4 
and CKD 5 versus standard treatment. The use of paricalcitol leads to an additional
medical cost of €4335 to €6564; and an increase in life years gained of 0.48 to 0.67
years, and a gain in QALYs of 0.42 to 0.64. Consequently the use of paricalcitol results
in an ICER of less than €11,000/QALY from the perspective of the society in all three 
countries. This value is well below the willingness to pay threshold. CONCLUSIONS:
The results showed that the favorable clinical beneﬁ t of paricalcitol results in positive 
short and long-term health economic beneﬁ ts. This study suggests that the use of 
paricalcitol in patients with early chronic kidney disease may be cost-effective from a 
society perspective in Italy, Portugal and Turkey.
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OBJECTIVES: A 12 week clinical trial (TIMES) demonstrated that therapy with 
tolterodine extended release (TOL)  tamsulosin (TAM) provides clinical beneﬁ ts 
versus TOL or TAM monotherapy or placebo (PBO) in men with lower urinary tract 
symptoms (LUTS) including overactive bladder (OAB). The present analysis estimated 
the costs and quality adjusted life years (QALYs) associated with these therapies from 
the perspective of the UK health care system. METHODS: TIMES cohorts receiving 
TOL, TAM, TOLTAM, or PBO were followed from therapy initiation to 12 weeks. 
A decision tree model was used to extrapolate the 12-week results to 1 year (including
need for surgery owing to treatment failure at 12 weeks), and to track patients’ out-
comes (symptoms, utility, and costs). Because TIMES did not include costs and 
QALYs, data from the EpiLUTS epidemiologic survey (9416 males) were used to 
model a mathematical relationship between LUTS (daytime and nocturnal frequency, 
urgency episodes, urgency urinary incontinence episodes, and International Prostate 
Symptom Scores [IPSS]), quality of life, and utility. This was used to convert improve-
ments in TIMES patients’ LUTS into utility scores and QALYs. The model included 
drug and surgery procedure costs and hospital length of stay. RESULTS: Incremental
QALYs of TOLTAM vs PBO, TAM and TOL were 0.033, 0.016 and 0.011, and
corresponding incremental costs were a262, a253 and -a30, respectively, resulting in 
cost-utility ratios for TOLTAM of a7,894/QALY gained compared with PBO, and 
a15,346/QALY gained compared with TAM. TOLTAM combination therapy was 
both more effective and cost-saving compared with TOL. Univariate sensitivity analy-
ses showed that patient utility was most responsive to changes in IPSS score and
number of urgency episodes. Changing the percentage of patients undergoing surgery 
did not substantially affect model outcomes. CONCLUSIONS: The TOLTAM com-
bination therapy appears to be cost-effective compared with TOL or TAM mono-
therapy or PBO in male patients with LUTS.
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OBJECTIVES: The calcineurin inhibitor (CNI) regimens, including tacrolimus or
cyclosporine, have improved the overall success of renal transplantation through 
increased short-term patient and graft survival. However, this has not translated into
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improved long-term outcomes due to the nephrotoxic effect of CNI regimens. A siro-
limus-based CNI withdrawal regimen may maximize the likelihood of long-term graft 
and patient survival. The goal of this study is to evaluate the cost-effectiveness of 
sirolimus regimen (sirolimuscyclosporinewithdrawal at three-monthsteroid) com-
pared with tacrolimus  mycofenolate mofetil(MMF)  Steroid regimen, and cyclo-
sporine MMF  steroid regimen in renal transplant patients in Korea. METHODS:
A Markov model simulates costs and outcomes in a hypothetical cohort of renal
transplant patients for 20 years with 5% discount rate. The model contain ﬁ ve health 
states: patient with graft survival, patient with graft failure, patient with regraft sur-
vival, patient with regraft failure and patient death. Short and long-term outcomes 
and utility weights were obtained from published literature, and quality adjusted life
years (QALYs) were used as an effectiveness measure. Resource utilizations and direct 
costs were calculated with the Korean public institutional data and clinical expert 
opinions. Sensitivity analyses were performed on crucial parameters. RESULTS: Siro-
limus regimen costs US$144,894 for the 8.055 QALYs for 20 years treatment dura-
tion, whereas US$173,234 for 6.399 QALYs for tacrolimus, and US$151,286 for
5.567 QALYs for cyclosporine. Sirolimus regimen was shown to be dominant, as it 
was more efﬁ cacious in QALYs and less costly than tacrolimus and cyclosporine
regimen. The results from the sensitivity analysis showed that the results were quite
robust across most parameters. Cost effectiveness was most sensitive to model dura-
tion. CONCLUSIONS: Sirolimus regimen shows not only potential clinical beneﬁ ts
for long-term but also is expected to be cost-saving over a patient’s life compared with 
the most frequently prescribed CNI regimens in Korea.
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OBJECTIVES: This study was conducted to evaluate the cost-effectiveness of Fes-
oterodine compared with Tolterodine in the treatment of OAB in Korea. The evalua-
tion was performed from the perspective of the statutory health insurer who will cover 
the direct costs of the drug upon approval and from societal viewpoint, as well. 
METHODS: Through a systematic review of preceding literature, we ﬁ rstly ﬁ gured 
out the factors that determine the efﬁ cacy for Fesoterodine and Tolterodine and sec-
ondly investigated whether Fesoterodine decreases symptom of OAB patients from 
randomized comparative trials with various comorbidities. Since there is no clinical
dataset of Fesoterodine along with Tolterodine for OAB patients in Korea, this study 
indirectly adopted the determinants and probabilities from the clinical results in all
languages for OAB treatment in order to estimate the treatment outcomes of the
selected comparators, and conducted the probabilistic sensitivity analysis. This study
also used to explore the cost-effectiveness of Fesoterodine in the following comorbidi-
ties: fracture, UTI, and depression. RESULTS: Based on the computed clinical success 
at week 12 of OAB treatment, Fesoterodine has higher performance than Tolterodine
by 18.44% point (56.50% vs. 38.06%) with a bit more total medical cost, though
(KRW 306,855 vs. KRW 260,457). In terms of cost-effectiveness ratio (CER), Fes-
oterodine has lower value than Tolterodine (KRW 5,431 vs. KRW 6,843), which 
implies that Fesoterodine is more cost-effective than Tolterodine in OAB treatment. 
Through the one-way sensitivity analysis varying the values of several controversial 
parameters such as resolution of incontinence, pad usage and frequency, and unit price
of pad, we could not ﬁ nd the reversal case in which Tolterodine outweighs Fesotero-
dine. CONCLUSIONS: Probabilistic analysis showed that OAB treatment with Fes-
oterodine is cost-effective in Korea compared to Tolterodine.
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OBJECTIVES: Overactive bladder (OAB) is a dysfunction of the lower urinary tract 
which causes signiﬁ cant impairment to patients’ QoL. Our study aim was to assess
the cost-effectiveness proﬁ le of Sacral neuromodulation (SNM), botulinum neurotoxin
(BoNT) and optimized medical treatment (OMT) in symptomatic idiopathic OAB 
patients with OMT experience in Spain. METHODS: A decision-analytic model was
built to simulate the clinical and economic consequences of initiating treatment for 
idiopathic OAB with SNM, BoNT or continue with OMT. Effectiveness (deﬁ ned in
terms of ‘improvement’, number of urinary incontinence episode and utility values) 
and model probabilities were obtained from literature; treatment pathways after initial
failure, resource use and assumptions were derived from local expert opinion. Due to
the lack of mid-long term efﬁ cacy data of BoNT, the most conservative assumptions
were included. The model was adjusted for a ten-year follow-up, to include the
neurostimulator battery change for SNM. Costs and effects were discounted at 3%.
RESULTS: OAB management with SNM may be associated with €12.18 and €2.62 
and per episode avoided and incremental cost-effectiveness ratios (ICERs) of 23,570€
and 1,573€ per Quality Adjusted Life Years (QALY) gained compared to OMT, at 
1 and 10 years respectively. SNM may also have a higher mid-long term effectiveness 
than BoNT at a reasonable cost, with ICERs of €29,450 and 9,287€ per QALY gained
at year 4 and 10, respectively. Probabilistic sensitivity analysis showed the robustness
of the results in SNM vs OMT, and due to the lack of BoNT efﬁ cacy data availability, 
an important variability in the results of SNM vs BoNT. CONCLUSIONS: SNM is 
effective in the treatment of OAB at a reasonable cost versus BoNT and OMT in
Spain. Further research is needed to assess the BoNT mid-long term effectiveness to
conﬁ rm the comparison versus SNM.
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OBJECTIVES: To evaluate the impact of a hypothetical renal health program (RHP) 
designed to delay initiation of renal replacement therapy (RRT). METHODS: We 
used a Markov model and Monte Carlo technique to simulate two simultaneous 1000 
patient cohorts assigned to a renal health program (RHP) or to “standard care” (SC). 
Population consisted of patients with hypertension and/or diabetes, with initial 
glomerular ﬁ ltration rate (GFR) between 60 and 15 ml min (stages 3 and 4 of 
chronic kidney disease [CKD]). We assumed that RHP had a monthly cost of two 
to four times that of SC, and that it reduced GFR loss in a proportion that we
called “the RHP effect”. The model incorporated 47 variables: 20 epidemiologic
variables, 19 cost variables (all at local Colombian rates) and 8 quality of life variables
(we used QALY established through experts’ consensus). We used a third-party
payer perspective, a 5-year time frame and a 3% annual discount rate both for 
costs and for utilities. RESULTS: Assuming a RHP 0.8 effect (equivalent to a 20%
GFR loss reduction) the average cost per patient was US$ 17,680 in RHP and US$ 
15,560 in SC. Average utility was higher in RHP (3.53 QALY) than in SC (3.45 
QALY). From the total of 1000 patients of the RHP group, 101 died compared with 
124 in the SC group. Additionally, along the ﬁ ve-year period, 242 subjects from the
RHP group required RRT compared with 310 from the SC group. Based on these
results, US$ 90,950 would be paid per death averted, US$ 27,200 per RRT averted 
and the incremental cost-effectiveness ratio would be US$ 21,450 per QALY gained. 
CONCLUSIONS: Five years is a short time. Return to investment would be seen only
in patients with advanced CKD. However, a RHP with a modest effect would still de 
cost-effective.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To determine the effects of oxybutynin chloride topical gel (OTG), a 
novel 10% ethanolic formulation, on health-related quality of life (HRQoL) in adults 
with overactive bladder (OAB). METHODS: Women and men aged q18 years with 
urge urinary incontinence were enrolled at 76 centers in a randomized, double-blind,
placebo-controlled, parallel-group study (00350636 at clinicaltrials.gov). Patients 
applied 1 g OTG once daily or matching placebo gel for up to 12 weeks. To assess 
HRQoL, investigators asked patients to complete 2 disease-speciﬁ c questionnaires
(Incontinence Impact Questionnaire [IIQ]; King’s Health Questionnaire [KHQ]) at 
baseline and weeks 1, 4, 8, and 12. Effects of OTG on HRQoL were assessed by 
computing mean change in questionnaire scores from baseline to week 12 or last
observation. Differences between active and placebo treatment were compared by
analysis of covariance. RESULTS: In this study completed May 2007, 704 women and
85 men were enrolled; 389 patients received OTG and 400 received placebo. IIQ total 
score improved signiﬁ cantly more in patients treated with OTG (mean change, 72.1 
points; P  .0005) than in those receiving placebo (mean change, 49.5 points). OTG
also improved HRQoL signiﬁ cantly more (P a .0078) than did placebo in all 4 IIQ 
subscales (Travel, Physical Activity, Social Relationships, and Emotional Health). 
Mean KHQ scores improved signiﬁ cantly more (P a .0489) with OTG than with 
placebo in 6 of 10 domains, many directly associated with OAB symptoms (Inconti-
nence Impact, Symptom Severity, Role Limitations, Personal Relationships, Sleep/
Energy, and Severity [Coping] Measures). Dry mouth was the most common treat-
ment-related adverse event in patients given OTG (27/389; 6.9%), but was not a
primary reason for any patient to stop treatment. CONCLUSIONS: OTG treatment 
signiﬁ cantly improved HRQoL in adults with OAB.
